Welcome to our dedicated page for Anebulo Pharmaceuticals SEC filings (Ticker: ANEB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the next clinical milestone or spotting insider sales before a data read-out shouldn’t mean combing through 200-page biotech disclosures. Anebulo Pharmaceuticals’ SEC filings are packed with trial data for ANEB-001, FDA pathway updates and cash-runway details—information critical to any investor tracking substance-abuse therapeutics but notoriously hard to parse.
Stock Titan solves that problem. Our AI engine turns dense documents into concise insights so you can move from question to answer in moments. Whether you need Anebulo Pharmaceuticals insider trading Form 4 transactions or an Anebulo Pharmaceuticals quarterly earnings report 10-Q filing, every submission hits our platform in real time, complete with plain-English summaries and key-metric callouts.
- Form 4 alerts showcase Anebulo Pharmaceuticals executive stock transactions Form 4 minutes after they post.
- 10-Q dashboards surface R&D spend trends, giving you an Anebulo Pharmaceuticals earnings report filing analysis without spreadsheets.
- 10-K drill-downs offer an Anebulo Pharmaceuticals annual report 10-K simplified view of clinical risks, patent life and liquidity.
- 8-K flash notes provide Anebulo Pharmaceuticals 8-K material events explained the same day management files them.
- Proxy tools clarify Anebulo Pharmaceuticals proxy statement executive compensation so you can benchmark pay against biotech peers.
Use our “understanding Anebulo Pharmaceuticals SEC documents with AI” feature to compare trial-stage progress quarter over quarter, track Anebulo Pharmaceuticals Form 4 insider transactions real-time, and spot red-flags before the market reacts. Complex biotech filings, finally clear.
Anebulo Pharmaceuticals (ANEB) reported Q1 FY2026 results with a net loss of $2,158,354 as it advances selonabant for cannabis-induced toxicity. Operating expenses were $2,260,260, with research and development at $809,991 (lower due to timing of studies) and general and administrative at $1,450,269 (higher from professional fees related to a potential going‑private transaction). Other income, net, was $101,906, aided by interest income.
Cash and cash equivalents were $10,354,773 as of September 30, 2025, and management believes this, along with availability under a $3,000,000 Loan Agreement accruing at 0.25% per annum, will fund operations for at least 12 months. No amounts were drawn under the facility. Net cash used in operating activities was $1,273,076 for the quarter.
The company received a notice of award on September 2, 2025 for Year 2 of its NIDA grant (approximately $1.0 million) to support IV selonabant development. Shares outstanding were 41,084,731 as of September 30, 2025. A Special Committee continues to evaluate strategic alternatives, including a proposed reverse stock split within a 1‑for‑2,500 to 1‑for‑7,500 range as part of a potential going‑private process.
Anebulo Pharmaceuticals (ANEB) is seeking shareholder approval for a reverse stock split at a board-determined ratio between 1-for-2,500 and 1-for-7,500, with the Board able to set the final ratio within that range or abandon the amendment. Fractional post-split shares will be cashed out at
The proxy explains the Board and a Special Committee considered market liquidity, valuation approaches (market and income methods), a fairness opinion from Houlihan Capital, and recent affiliate purchases (private placement at
Anebulo Pharmaceuticals (ANEB) filed its Form 10-K reporting 41,084,731 shares outstanding and a market value of approximately $15,057,677 based on the Nasdaq close on December 31, 2024. The company recorded an accumulated deficit of $73.9 million as of June 30, 2025 and expects to continue generating operating losses. Management states cash, cash equivalents and available funding under its Loan Agreement should fund operations for at least 12 months from issuance of the financial statements. During the year the company completed a private placement of 15,151,514 shares for gross proceeds of about $15.0 million and issued warrants exercisable at $4.215 until September 28, 2027. Grant income of $0.9 million was recognized and a Loan Agreement providing up to $10 million remains available with no balance outstanding at June 30, 2025.
Anebulo Pharmaceuticals seeks stockholder approval for a reverse stock split at a ratio set within a 1-for-2,500 to 1-for-7,500 range, with the Board able to pick the exact ratio or abandon the amendment. Fractional post-split shares will be cashed out at $3.50 per share. At a midpoint 1-for-5,000 ratio, the company estimates approximately $4.1 million will be required to retire fractional shares; low and high estimates are $3.2 million and $4.7 million, respectively, plus estimated Transaction fees of about $1.0 million. The company expects to pay these amounts from cash on hand, which on March 31, 2025 included $13.3 million of cash and equivalents and $3.0 million of debt. The Special Committee obtained a fairness opinion from Houlihan Capital and noted that the $3.50 Cash Payment represents a premium to recent prices (111% to the July 11, 2025 close of $1.66; 116% to 30‑day VWAP of $1.62; 150% to 90‑day VWAP of $1.40). The proxy discloses concentrated ownership (e.g., 22NW ~40.1% and a director Aron R. English ~51.2% beneficially) and pro forma outstanding shares post-split (pro forma example: 7,980 shares after a 1-for-5,000 split).
FAQ
What is the current stock price of Anebulo Pharmaceuticals (ANEB)?
What is the market cap of Anebulo Pharmaceuticals (ANEB)?
